Caribou Biosciences, Inc. (NASDAQ:CRBU) Short Interest Up 13.7% in December
by Sarita Garza · The Markets DailyCaribou Biosciences, Inc. (NASDAQ:CRBU – Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 9,800,000 shares, a growth of 13.7% from the November 30th total of 8,620,000 shares. Based on an average daily volume of 1,340,000 shares, the short-interest ratio is currently 7.3 days. Approximately 12.4% of the shares of the stock are sold short.
Caribou Biosciences Trading Down 1.2 %
Shares of NASDAQ:CRBU traded down $0.02 during trading on Wednesday, reaching $1.59. The company’s stock had a trading volume of 1,714,111 shares, compared to its average volume of 1,690,717. Caribou Biosciences has a 12 month low of $1.50 and a 12 month high of $8.33. The firm’s 50 day simple moving average is $2.04 and its two-hundred day simple moving average is $2.00. The stock has a market capitalization of $143.98 million, a PE ratio of -0.96 and a beta of 2.27.
Caribou Biosciences (NASDAQ:CRBU – Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. The business had revenue of $2.02 million for the quarter, compared to the consensus estimate of $3.37 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. Research analysts anticipate that Caribou Biosciences will post -1.64 EPS for the current fiscal year.
Hedge Funds Weigh In On Caribou Biosciences
Several hedge funds have recently bought and sold shares of CRBU. Barclays PLC lifted its holdings in Caribou Biosciences by 122.4% during the 3rd quarter. Barclays PLC now owns 129,839 shares of the company’s stock valued at $255,000 after buying an additional 71,463 shares in the last quarter. Geode Capital Management LLC boosted its position in Caribou Biosciences by 6.5% during the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after acquiring an additional 124,782 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in shares of Caribou Biosciences during the 3rd quarter worth $28,000. PFM Health Sciences LP boosted its position in Caribou Biosciences by 5.5% during the third quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock valued at $8,441,000 after purchasing an additional 223,299 shares in the last quarter. Finally, Walleye Capital LLC grew its stake in Caribou Biosciences by 45.9% in the third quarter. Walleye Capital LLC now owns 237,599 shares of the company’s stock valued at $466,000 after purchasing an additional 74,799 shares during the last quarter. Institutional investors own 77.51% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on CRBU shares. Citigroup decreased their price target on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 26th. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Caribou Biosciences in a research report on Friday, November 15th. Four research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $10.20.
Get Our Latest Stock Report on CRBU
Caribou Biosciences Company Profile
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Featured Articles
- Five stocks we like better than Caribou Biosciences
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Work and Play: Investing in the Rise of Bleisure Travel
- What Investors Need to Know to Beat the Market
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- ESG Stocks, What Investors Should Know
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business